Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal

Core Viewpoint - Novo Nordisk has confirmed compliance with all restrictions under the Pfizer merger agreement in its unsolicited offer for Metsera, emphasizing that the value of its proposal significantly exceeds expectations [1] Group 1 - Novo Nordisk's unsolicited offer for Metsera is positioned as a strategic move within the pharmaceutical industry [1] - The company asserts that its proposal's value is substantially higher than that of competitors, indicating a strong competitive stance [1] - Compliance with the Pfizer merger agreement restrictions highlights Novo Nordisk's commitment to regulatory standards in its acquisition strategy [1]